NOT-AG-21-022: Notice of Change: Extension for PAR-18-820, "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)"

Notice of Change: Extension for PAR-18-820, "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)"

Notice Number:

NOT-AG-21-022

Key Dates

Release Date:

April 28, 2021

Related Announcements

PAR-18-820 - Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Issued by

National Institute on Aging (NIA)

Purpose

This Notice informs potential applicants that the expiration date for Funding Opportunity Announcement (FOA) PAR-18-820 "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)" will be extended by one receipt cycle. The FOA now expires on January 8, 2022.

The following Section of PAR-18-820 has been modified:

Part 1. Overview Information

Key Dates

Currently Reads:

Expiration Date: September 8, 2021

Modified to Read (changes shown in bold italics):

Expiration Date: January 8, 2022

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Lorenzo M. Refolo, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-594-7576
Email: [email protected]